Ocular Therapeutix, Inc. (OCUL) Reaches $5.60 After 9.00% Up Move; 0 Bullish Analysts Covering Hugo Boss AG (BOSSY)

January 14, 2018 - By Linda Rogers

The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a huge mover today! The stock increased 14.05% or $0.69 during the last trading session, reaching $5.6. About 985,045 shares traded or 145.03% up from the average. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has declined 9.50% since January 14, 2017 and is downtrending. It has underperformed by 26.20% the S&P500.The move comes after 9 months positive chart setup for the $164.85M company. It was reported on Jan, 14 by Barchart.com. We have $6.10 PT which if reached, will make NASDAQ:OCUL worth $14.84 million more.

Among 3 analysts covering Hugo Boss AG (OTCMKTS:BOSSY), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Hugo Boss AG had 4 analyst reports since October 20, 2016 according to SRatingsIntel. As per Thursday, October 20, the company rating was upgraded by BNP Paribas. As per Thursday, February 9, the company rating was downgraded by BNP Paribas. Citigroup downgraded the shares of BOSSY in report on Friday, January 13 to “Neutral” rating. RBC Capital Markets upgraded Hugo Boss AG (OTCMKTS:BOSSY) on Tuesday, February 21 to “Sector Perform” rating. See Hugo Boss AG (OTCMKTS:BOSSY) latest ratings:

HUGO BOSS AG, together with its subsidiaries, develops, markets, and distributes fashion and accessories for men and women worldwide. The company has market cap of $5.88 billion. It offers classic to modern apparel, eveningwear, sportswear, shoes, and leather accessories, as well as licensed fragrances, eyewear, watches, childrenÂ’s fashion, home textiles, and writing instruments. It has a 19.83 P/E ratio. The firm markets and sells its products under the BOSS, BOSS Orange, BOSS Green, and HUGO brand names through online stores, freestanding stores, and shop-in-shops with approximately 7,700 points of sale.

The stock decreased 0.39% or $0.067 during the last trading session, reaching $17.203. About 18,469 shares traded or 537.30% up from the average. Hugo Boss AG (OTCMKTS:BOSSY) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. The company has market cap of $164.85 million. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. It currently has negative earnings. The companyÂ’s lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Analysts await Ocular Therapeutix, Inc. (NASDAQ:OCUL) to report earnings on March, 9. They expect $-0.58 EPS, down 11.54% or $0.06 from last year’s $-0.52 per share. After $-0.54 actual EPS reported by Ocular Therapeutix, Inc. for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.

Among 8 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Ocular Therapeutix had 21 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Tuesday, November 7 with “Buy”. The stock has “Buy” rating by Cantor Fitzgerald on Monday, July 10. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Equal-Weight” rating by Morgan Stanley on Friday, June 23. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Hold” rating by BTIG Research on Wednesday, August 2. The stock has “Overweight” rating by Morgan Stanley on Thursday, April 28. The firm has “Buy” rating given on Wednesday, August 5 by Nomura. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, July 14. The stock has “Outperform” rating by JMP Securities on Thursday, August 11. Guggenheim initiated Ocular Therapeutix, Inc. (NASDAQ:OCUL) on Monday, October 23 with “Buy” rating. The stock has “Overweight” rating by Cantor Fitzgerald on Friday, February 10.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts